Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Antimicrobial susceptibilities of Acinetobacter species causing invasive infections in children

From: Molecular epidemiology of Acinetobacter baumannii complex causing invasive infections in Korean children during 2001–2020

 

No. of cases (%)

Non-AB

(n = 48)

AB non-CC92

(n = 8)

AB CC92

(n = 52)

Ceftazidime

41 (85.4))

8 (100)

1 (1.9)

Cefepime

43 (89.6)

7 (87.5)

1 (1.9)

PIP/TAZ

41 (85.4))

7 (87.5)

1 (1.9)

Imipenem

47 (97.9)

7 (87.5)

3 (5.8)

Amikacin

44 (91.7)

8 (100)

12 (23.1)

Ciprofloxacin

47 (97.9)

8 (100)

1 (1.9)

TMP/SMZ

38 (79.2)

7 (87.5)

6 (11.5)

Colistin

-

3 (37.5)

21 (40.4)

  1. AB, A. baumannii; CC, clonal complex; PIP/TAZ, piperacillin/tazobactam;
  2. TMP/SMZ, trimethoprim/sulfamethoxazole